Rafarma and Haifa Technopark Enter Talks for Joint Venture
Rafarma Pharmaceuticals (OTC: RAFA) announced on April 26, 2021, the initiation of negotiations with Matam Technopark in Haifa, Israel. The collaboration aims to develop and adapt pharmaceutical technologies, focusing on Exosome research and the creation of modified bacteria for new drug designs. Chairman Ilya Spurov emphasized the company's commitment to engaging with global pharmaceutical partners to enhance its biotech market presence. The Matam Technopark is notable for housing major tech firms like Amazon and Microsoft, representing a significant opportunity for Rafarma's growth.
- Partnership with Matam Technopark to enhance pharmaceutical technology.
- Focus on innovative research, including Exosome technology and modified bacteria.
- None.
Nicosia, Cyprus, April 30, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that on April 26, 2021 the company entered negotiations and formed an action plan with the Matam Technopark in Haifa, Israel (https://www.gav-yam.co.il/en/projects/gav-yam-haifa-bay) to pursue joint development, acquisition and adaptation of pharmaceutical technologies. The companies are exploring Exosome research for pharmaceutical production and use, as well as joint research toward an artificially-created, modified bacterium to form a therapeutic platform for new drug designs.
Chairman Ilya Spurov commented: “Rafarma continues to engage with the best pharmaceutical partners around the globe to expand its presence in the biotech market.”
The Matam Technopark is part of the “Silicon Wadi” (Valley) of Israel, which also houses Amazon, Intel, Microsoft, Yahoo!, Philips, Google, Qualcomm, Apple and other technology giants.
Matam Technopark in Haifa Israel
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029
Attachment
FAQ
What is the latest news about Rafarma Pharmaceuticals (RAFA)?
What are Rafarma's plans with Matam Technopark?
When was the partnership between Rafarma and Matam Technopark announced?
How does the Matam Technopark contribute to Rafarma's strategy?
